Tirzepatide (Mounjaro and Zepbound) at the 15 mg dose showed comparable lean-mass loss in pattern but modestly less in proportion (approximately 25% of total weight loss as lean mass
If you are new to supplements and want a personalized starting point, our Health Quiz can help guide your routine
The side effect profile is similar in type, with nausea, constipation, and diarrhea being most common, but the severity and tolerability may differ due to the different receptor activation pattern
Results A total of 19,199 patients from 63 studies using VCTE showed diagnostic AUC of 0.83 (95% confidence interval: 0.800.86), 0.83 (0.800.86), 0.87 (0.840.90), and 0.94 (0.910.96) for F1, F2, F3, and F4 stages, respectively